 |
The newly designed E3002 Ang Femtocataract Corneal Dissector is double-ended, designed to open sticky corneal incisions performed during femtosecond cataract surgery. The dissector’s fine, rounded-end bent hook can penetrate either primary or secondary sticky incisions. The other end of the dissector is leaf shaped and designed for use on the primary and corneal incision. This end is placed on the lip of the primary incision, depressed and pushed inward to open the incision with a side-to-side motion.
The newly designed E9110 MacRae LASIK Flap Spatula is also double-ended and a multi-use tool for LASIK procedures. The small, blunt tip is designed to separate the stromal layer. The second tip features a long, horizontal tip designed to aid in lifting the corneal flap during the procedure.
Finally, the company has also introduced the newly designed E3130 Desai DSEK Forceps, designed for use in Descemet’s Stripping Endothelial Keratoplasty, to transfer the donor tissue from the inserter into the patient’s anterior chamber. Intended for use with ET8198H StableGrip Vitroretinal Handle (sold separately), the 23-ga. forceps feature tissue-friendly, gentle- grip jaws and an attached cannula to irrigate the eye and expand the graft. For more information, visit storzeye.com or call 1 (800) 338-2020.
Addition to Ocusoft Lid Scrubs Benefits Most Severe Cases
Ocusoft introduces Ocusoft HypoChlor, a 0.02% concentration of hypochlorous acid available in both solution and gel formulation that can be used to supplement the Ocusoft Lid Scrub family of eyelid cleansers in the most severe cases of blepharitis.
While hypochlorous acid may offer some benefit in the most severe conditions, it lacks the surfactant activity found in both Ocusoft Lid Scrub Original and Plus formulas. The root cause of anterior blepharitis is the overproduction of oils, which harbor bacteria that cause inflammation of the lids. The key to reducing bacterial flora is to remove the excessive oils from the eyelids and follow with use of antibacterials to reduce the bacteria population.
 |
For information, visit ocusoft.com.
New Laser and Suturing Options from Iridex
Iridex Corp. announced that the U.S. Patent and Trademark Office granted a patent for its new proprietary disposable device intended to replace certain suturing techniques in eye surgery. The iClip Closure Device will initially be focused on trabeculectomies and is intended to expand to a broader range of ophthalmic surgical procedures in the future.
“Eye surgery is a very delicate and precise process,” stated co-inventor Steven Vold, MD, cataract and glaucoma specialist. “The new iClip technology is intended to drive efficiencies in multiple procedures with an initial focus in glaucoma.”
The company also reported the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma-dedicated laser along with a family of single-use probes, including the newly patented MicroPulse P3 disposable. Iridex says the Cyclo G6 offers repeatable and minimally invasive approaches to slowing the progress of the disease.
“Glaucoma is a chronic disease that requires careful management to preserve a patient’s vision long term,” stated glaucoma and cataract specialist Robert Noecker, MD, of the Ophthalmic Consultants of Connecticut. “The procedure performed with the new MicroPulse P3 disposable demonstrated safety and clinical efficacy without the need for incisional surgery.”
For information, visit iridex.com.
Reichert Debuts Advanced Phoropter VRx System
Reichert Technologies announced the commercial introduction of the highly anticipated Phoroptor VRx Digital Refraction System, which it calls the most advanced phoroptor ever built. The system’s logically and ergonomically arranged keypad and multi-functional knob, coupled with an intuitive user interface and tilting touchscreen, provide operators with the tools needed to drive improved practice efficiency.
The system features a bright, full-color, 10.4-in. tilting touchscreen and intuitive user interface that provide operators with the flexibility to easily access any tests during the exam process. With effortless integration to both EMR and pre-test equipment, Phoroptor VRx helps to deliver what may be the shortest refraction on the market, Reichert says.
Phoroptor VRx boasts premium motors for extremely fast and ultra-quiet lens exchanges, as well as new features like motorized prism compensators and a split cylinder lens to facilitate faster testing for astigmatic correction.
For information, watch the full-length product video on Reichert’s YouTube channel, call 1(888) 849-8955 or visit reichert.com.
FDA Approval for Absorbable and Non-Absorbable Sutures
U.S. IOL Inc. received FDA approval for domestic sale of its highly popular line of Absorbable and Non-Absorbable sutures. The sutures feature high-strength, burr-free, stainless-steel needles with maximum form stability. Suture threads are specially coated for a smooth, drag-free passage through tissue.
For information, visit usiol.com.
Positive Top-Line Results from Two Kala Clinical Trials
Kala Pharmaceuticals released positive top-line results of two clinical trials of KPI-121, a nanoparticle loteprednol etabonate MPP (mucus-penetrating particle) product candidate.
In a Phase III clinical trial of KPI-121 for the treatment of inflammation and pain in patients who have undergone cataract surgery, KPI-121 achieved all primary efficacy endpoints and was generally well-tolerated, with no significant treatment-related safety findings observed during the course of the trial.
The multicenter, randomized, double-masked, vehicle-controlled, parallel-group trial in 380 patients was designed to evaluate two dosing regimens of KPI-121 ophthalmic suspension versus vehicle. Patients were randomized to receive either 0.25% KPI-121 q.i.d., 1.0% KPI-121 b.i.d. or their corresponding vehicles administered for two weeks.
At day eight, statistically significant differences favoring KPI-121 were achieved for the primary endpoint of complete resolution of inflammation with both 1% KPI-121 dosed twice a day (p=0.0024) and 0.25% KPI-121 dosed q.i.d. (p<0.0001). Complete resolution of ocular pain by day eight (also a primary endpoint) was achieved for 1% KPI-121 dosed b.i.d. (p=0.0019) and 0.25% KPI-121 dosed q.i.d. (p=0.0003).
In a Phase II clinical trial of KPI-121 in patients with dry-eye disease, KPI-121 achieved statistical significance for the primary sign endpoint, and promising trends were observed for key symptom endpoints.
The multicenter, randomized, double-masked, parallel-group trial compared 0.25% KPI-121 to vehicle, each dosed q.i.d. for 28 days, in 150 patients with dry-eye disease. The treatment group achieved statistical significance for the primary clinical sign endpoint of bulbar conjunctival hyperemia at day 29 of the trial (p=0.0387). Although KPI-121 did not achieve statistical significance for the primary symptom endpoint of ocular discomfort, the trial showed promising trends toward improvement in this and other symptom endpoints, particularly in patients with more severe baseline ocular discomfort. KPI-121 was generally well-tolerated, with no significant treatment-related safety findings observed during the course of the trial.
The only treatment-emergent adverse event reported in greater than 3 percent of patients was instillation site pain, which was reported in 6.9 percent of patients treated with KPI-121 compared to 3.8 percent of patients treated with vehicle.
For more information, visit kalarx.com. REVIEW
